Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Return on Capital Employed came in at 36.14% in Q2 2026, up 79.0% YoY from 20.19% in Q2 2025, and up 5.13% on a QoQ basis from 38.1% in Q1 2026.
Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 8 years of Return on Capital Employed data on file, last reported at 36.14% in Q2 2026.
- Quarterly Return on Capital Employed rose 79.0% year-over-year to 36.14% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 36.14% (up 79.0% YoY) and the FY2025 annual result came in at 31.66%, down 206.0% from the prior year.
- Return on Capital Employed advanced to 36.14% in Q2 2026, from 38.1% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 17.73% in Q1 2022 to a low of 39.79% in Q3 2025.
- A 5-year average of 31.2% and a median of 34.58% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 1509 bps — and 2025, when it slumped 1956 bps.
- Tracing BCYC's Return on Capital Employed over 5 years: stood at 32.36% in 2022, then fell by 7 bps to 34.69% in 2023, then surged by 33 bps to 23.07% in 2024, then slumped by 57 bps to 36.13% in 2025, then decreased by 0 bps to 36.14% in 2026.
- The last three Return on Capital Employed figures came in at 36.14% (Q2 2026), 38.1% (Q1 2026), and 36.13% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -36.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.14% |
| Mar 31, 2026 | -38.10% |
| Dec 31, 2025 | -36.13% |
| Sep 30, 2025 | -39.79% |
| Jun 30, 2025 | -36.93% |
| Mar 31, 2025 | -28.79% |
| Dec 31, 2024 | -23.07% |
| Sep 30, 2024 | -20.24% |
| Jun 30, 2024 | -25.03% |
| Mar 31, 2024 | -34.47% |
| Dec 31, 2023 | -34.69% |
| Sep 30, 2023 | -35.23% |
| Jun 30, 2023 | -39.78% |
| Mar 31, 2023 | -35.74% |
| Dec 31, 2022 | -32.36% |
| Sep 30, 2022 | -26.29% |
| Jun 30, 2022 | -21.16% |
| Mar 31, 2022 | -17.73% |
| Dec 31, 2021 | -19.06% |
| Sep 30, 2021 | -28.93% |